<VariationArchive VariationID="439123" VariationName="NM_000517.6(HBA2):c.69del (p.Glu24fs)" VariationType="Deletion" Accession="VCV000439123" Version="13" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-07-29" DateCreated="2017-09-30" MostRecentSubmission="2023-03-04">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="432844" VariationID="439123">
      <GeneList>
        <Gene Symbol="HBA2" FullName="hemoglobin subunit alpha 2" GeneID="3040" HGNC_ID="HGNC:4824" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="172876" stop="173710" display_start="172876" display_stop="173710" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="222845" stop="223708" display_start="222845" display_stop="223708" Strand="+" />
          </Location>
          <OMIM>141850</OMIM>
        </Gene>
        <Gene Symbol="LOC106804612" FullName="hemoglobin subunit alpha 2 recombination region" GeneID="106804612" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="170362" stop="173729" display_start="170362" display_stop="173729" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000517.6(HBA2):c.69del (p.Glu24fs)</Name>
      <CanonicalSPDI>NC_000016.10:172980:C:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="172981" stop="172981" display_start="172981" display_stop="172981" variantLength="1" positionVCF="172980" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="222980" stop="222980" display_start="222980" display_stop="222980" variantLength="1" positionVCF="222979" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>E24fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.172981del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.172981del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.222980del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.222980del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_000006.1" sequenceAccession="NG_000006" sequenceVersion="1" change="g.33844del">
            <Expression>NG_000006.1:g.33844del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046165.1" sequenceAccession="NG_046165" sequenceVersion="1" change="g.2720del">
            <Expression>NG_046165.1:g.2720del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_059186.1" sequenceAccession="NG_059186" sequenceVersion="1" change="g.1331del">
            <Expression>NG_059186.1:g.1331del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_059271.1" sequenceAccession="NG_059271" sequenceVersion="1" change="g.5135del">
            <Expression>NG_059271.1:g.5135del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000517.6" sequenceAccession="NM_000517" sequenceVersion="6" change="c.69del" MANESelect="true">
            <Expression>NM_000517.6:c.69del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000508.1" sequenceAccession="NP_000508" sequenceVersion="1" change="p.Glu24fs">
            <Expression>NP_000508.1:p.Glu24fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1225" sequenceAccession="LRG_1225">
            <Expression>LRG_1225:g.1331del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1240" sequenceAccession="LRG_1240">
            <Expression>LRG_1240:g.5135del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1240t1" sequenceAccession="LRG_1240t1">
            <Expression>LRG_1240t1:c.69del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1240p1" sequenceAccession="LRG_1240p1" change="p.Glu24fs">
            <Expression>LRG_1240p1:p.Glu24fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA620304238" DB="ClinGen" />
        <XRef Type="rs" ID="1270810159" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00006" Source="The Genome Aggregation Database (gnomAD), exomes" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000517.6(HBA2):c.69del (p.Glu24fs) AND not provided" Accession="RCV000507788" Version="17">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-08-23" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000517.6(HBA2):c.69del (p.Glu24fs) AND alpha Thalassemia" Accession="RCV001027962" Version="9">
        <ClassifiedConditionList TraitSetID="4863">
          <ClassifiedCondition DB="MedGen" ID="C0002312">alpha Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2019-05-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-08-23" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2017-09-30" MostRecentSubmission="2023-03-04">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16512835</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17486494</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20507641</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31025160</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="4863" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="6489" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Alpha thalassemia spectrum</ElementValue>
                <XRef ID="MONDO:0011399" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">A-Thalassemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">alpha Thalassemia</ElementValue>
                <XRef ID="Alpha-Thalassemia/333" DB="Genetic Alliance" />
                <XRef ID="68913001" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="621" />
                <XRef ID="621" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome (caused by deletion/inactivation of all four α-globin genes; --/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three α-globin genes; --/-α). Hb Bart syndrome, the more severe form, is characterized by prenatal onset of generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common. Death usually occurs in the neonatal period. HbH disease has a broad phenotypic spectrum: although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual. The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to infections or exposure to oxidant drugs.</Attribute>
                <XRef ID="NBK1435" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301608</ID>
                <ID Source="BookShelf">NBK1435</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <XRef ID="846" DB="Orphanet" />
              <XRef ID="C0002312" DB="MedGen" />
              <XRef ID="MONDO:0011399" DB="MONDO" />
              <XRef Type="MIM" ID="604131" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2348906" SubmissionDate="2019-06-10" DateLastUpdated="2020-03-29" DateCreated="2020-03-29">
        <ClinVarSubmissionID localKey="NM_000517.4:c.69delC|Alpha thalassemia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001190709" DateUpdated="2020-03-29" DateCreated="2020-03-29" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-05-20">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000517.4:c.69delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Alpha thalassemia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Natera0001</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1164917" SubmissionDate="2021-12-29" DateLastUpdated="2022-01-03" DateCreated="2017-09-30">
        <ClinVarSubmissionID localKey="S6580|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000601222" DateUpdated="2022-01-03" DateCreated="2017-09-30" Type="SCV" Version="2" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-01-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">31025160</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16512835</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17486494</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20507641</ID>
          </Citation>
          <Comment>This variant causes the premature termination of HBA2 protein synthesis, and has been reported in heterozygous carriers with mild microcytic anemia in the published literature (PMIDs: 16512835 (2006) and 17486494 (2007)). Functional studies showed that this variant does not affect RNA splicing, but the mRNA transcript is subject to nonsense-mediated decay (PMID: 16512835 (2006)). Therefore, the variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000517.4:c.69del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10813355</SubmissionName>
          <SubmissionName>SUB2915479</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4015132" SubmissionDate="2023-01-06" DateLastUpdated="2023-03-04" DateCreated="2022-01-08">
        <ClinVarSubmissionID localKey="3042701|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002048279" DateUpdated="2023-03-04" DateCreated="2022-01-08" Type="SCV" Version="3" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The HBA2 c.69delC; p.Glu24SerfsTer26 variant (rs1270810159), also known as codon 22 (-C), is reported in the literature in the heterozygous state in individuals with microcytic and hypochromic anemia (Luo 2007, Pereira 2006). This variant is also reported in ClinVar (Variation ID: 439123). This variant is found in the general population with an overall allele frequency of 0.006% (3/53510 alleles) in the Genome Aggregation Database. This variant causes a frameshift by deleting a single nucleotide, and has been shown to result in a truncated mRNA subject to nonsense-mediated decay (Pereira 2006). Based on available information, this variant is considered to be pathogenic. References: Luo HY et al. Two new alpha-thalassemia frameshift mutations. Hemoglobin. 2007;31(2):135-9. PMID: 17486494. Pereira FJ et al. Human alpha2-globin nonsense-mediated mRNA decay induced by a novel alpha-thalassaemia frameshift mutation at codon 22. Br J Haematol. 2006 Apr;133(1):98-102. PMID: 16512835.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/ythvkvge/arup_molecular_germline_variant_investigation_process_2021.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.222980del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2022 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>ARUP Molecular 2021</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1164917" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4015132" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2348906" TraitType="Disease" MappingType="Name" MappingValue="Alpha thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

